Enlarge image 21/21; Swiss

Orphan diseases Switzerland

Dr. Rudolph Widmann established AOP Orphan in Vienna in 1996 in order to provide individualized treatments for patients suffering from Rare Diseases. AOP Orphan has especially focused in the areas of hematology and oncology, cardiology, pulmonology, neurology, psychiatry and metabolic diseases.

Thanks to 15 years of experience in complex individualized treatments, AOP Orphan has obtained exceptional competence as well as market presence in the field of Orphan Diseases. The fact that AOP Orphan is privately owned assures a long-term engagement in the market along with high quality services and products. AOP Orphan is also the only provider of key therapies for certain special indications.

AOP Orphan experts work closely at an international level with leading health care professionals. This has given them the ability to react quickly towards needs and developments and to push research and development projects forward. When implementing these projects, AOP Orphan has a worldwide network of highly qualified partners that it can reach out to. These strategical alliances make sure that AOP Orphan as a middle-sized enterprise is able to compete with top-pharmaceutical companies.

AOP Orphan is currently one of the leading suppliers in the pharmaceutical industry, and as an international Austrian business, AOP Orphan generates sales of more than 50 million Euros. The company has an export quota of around 70% and over 100 employees. AOP Orphan’s branch offices are situated within its core markets in the EU, Switzerland, and the Middle East. Overall AOP Orphan has offices in 12 different regions. The international markets are handled and operated by close partners of AOP Orphan.

The company is led by the founder Dr. Rudolph Widmann, as well as Dr. Georg Fischer, Dr. Christoph Klade, Mag. Karin Pernkopf, Ms. Elfriede Gumplmayr and Douglas Lloyd-Fell.

In the branch of Hematology and Oncology, AOP Orphan focuses on myeloproliferative disorders—a group of malignant hematologic disorders that lead to the degeneration of the hematopoetic cells in the myeloid cell line.

  • Essential Thrombocythemia—a Rare Disease of the hematopoetic system in the bone marrow that causes an overproduction of platelets (thrombocytes) in the blood.
  • Polycythemia Vera—in this case there is a progressive increase in the production of erythrocytes (red blood cells). Most often an increase in the leukocytes and thrombocytes occurs as well.
  • Primary Myelofibrosis—pri myelofibrosis develops into a progressive scarring of the bone marrow, which is often accompanied by anemia.
  • Chronic Myelogenous Leukemia (CML)—CML is a malignant blood disease that has a slow progression rate. It is caused by the clonal expansion of diseased blood stem cells which cause the overproduction of white blood cells (leukocytes).

Popular Q&A

avatar
Why Join A Rare Disease Support Group?

Joining a rare disease support group can be helpful for people dealing with illnesses and problems few other people have. If you don't already belong to a support group, here are some reasons why you might want to join one.

Related Posts